Angle upbeat on research into Parsortix with melanoma patients
11th Feb 2020 07:41
(Sharecast News) - Liquid biopsy company Angle announced on Tuesday that a customer, the Edith Cowan University in Perth, Western Australia, has published results of research into the use of its 'Parsortix' system with melanoma patients.
Read moreAngle upbeat on patent grant for prostate cancer blood assessment
4th Oct 2019 15:17
(Sharecast News) - Liquid biopsy company Angle announced on Friday that the Queen Mary University of London (QMUL) European patent covering the measurement of the number of megakaryocytes in a patient blood sample as an assessment of the prognosis for prostate cancer has been granted.
Read moreAngle initiates main phase of ovarian cancer clinical study
29th Aug 2019 09:12
(Sharecast News) - Liquid biopsy company Angle announced on Friday that the main phase of its 200-patient ovarian cancer clinical verification study has been initiated and the first patient has been enrolled.
Read moreAngle looks to strengthen balance sheet and extend runway via placement
25th Jun 2019 08:16
(Sharecast News) - Liquid biopsy company Angle will look to raise up £18m at 61.5p per ordinary share through finnCap and WG Partners in order to strengthen its balance sheet and enable the development of key products.
Read moreAngle upbeat on recent cancer research results
21st Jun 2019 15:26
(Sharecast News) - Liquid biopsy company Angle announced on Friday that the University Medical Centre Hamburg-Eppendorf (UKE) cancer centre has published results of work demonstrating that its 'Parsortix' system can be used as a liquid biopsy to investigate programmed death-ligand 1 (PD-L1) status in non small cell lung cancer (NSCLC) patients.
Read moreAngle reveals positive results from latest Parsortix study
31st May 2019 09:53
(Sharecast News) - Liquid biopsy company Angle announced positive results from its 'Parsortix' FDA clinical study for metastatic breast cancer on Friday.
Read moreAngle's Parsortix system used in more groundbreaking research
26th Apr 2019 12:48
(Sharecast News) - Liquid biopsy company Angle announced on Friday that its 'Parsortix' system has been utilised in further groundbreaking new cancer research, demonstrating the role of myeloid-derived suppressor cells (MDSCs) as part of large circulating tumor cell (CTC) clusters, which are 50x more likely to generate metastasis than single CTCs, for the first time.
Read moreAngle's Parsortix to be used in new Greece study
12th Apr 2019 15:25
(Sharecast News) - Liquid biopsy company Angle announced on Friday that a leading customer has established a multi-centre study to investigate biomarkers on circulating tumor cells (CTCs), using its 'Parsortix' system, which could give advance warning of relapse in non small cell lung cancer (NSCLC).
Read moreAngle completes enrolment in Parsortix breast cancer study
7th Mar 2019 09:35
(Sharecast News) - Liquid biopsy company Angle announced on Thursday that enrolment for its 'Parsortix' FDA clinical study for metastatic breast cancer was now complete.
Read moreAngle client demonstrates new use for 'Parsortix' system
25th Feb 2019 10:51
(Sharecast News) - Liquid biopsy company Angle said on Monday that one of its leading customers, the Disseminated Cancer Cell Network (DCCNet) in Duesseldorf, has published new results in a peer-reviewed journal of work done to harvest circulating tumor cells (CTCs) from diagnostic leukapheresis (DLA) samples.
Read moreAngle's 'Parsortix' used in new groundbreaking cancer research
11th Feb 2019 11:35
(Sharecast News) - Liquid biopsy company Angle announced on Monday that its 'Parsortix' system had been utilised in further "groundbreaking" cancer research into CTC clusters, reportedly demonstrating that the patient's own immune cells (neutrophils) could actively help the process of metastasis by which the cancer spread.
Read moreAngle sees 'highly encouraging' results from prenatal testing
29th Oct 2018 11:08
(Sharecast News) - Medical diagnostics outfit Angle is talking to "several interested parties" to commercialise its testing device after a "highly encouraging" trial indicated it could be adapted as a non-invasive prenatal test.
Read moreAngle makes 'good progress' with ANG-002 patient enrolment
25th Oct 2018 08:52
(Sharecast News) - Liquid biopsy company Angle announced on Thursday that patient enrolment for its ANG-002 FDA clinical study for metastatic breast cancer had continued to make good progress.
Read moreAngle selected for European cancer ID programme
13th Feb 2017 08:55
(ShareCast News) - Medical technology company Angle has been chosen to take part in Cancer-ID, a European consortium to validate blood-based biomarkers for cancer, by providing a number of Parsortix instruments and associated consumables for evaluation. The evaluation phase, which runs until 2020, w
Read moreAngle initiates 200 patient European ovarian cancer study
19th Jul 2016 12:56
(ShareCast News) - Medical technology company Angle's European ovarian cancer study has been formally initiated with a first patient recruited. Angle completed the process required to initiate this study, which included optimising the system protocols for the application, development and approval of
Read more